Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Aug 29;12(2):91–99. doi: 10.1111/j.1527-3458.2006.00091.x

Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical Data

Mauro A M Carai 1,2,✉, Giancarlo Colombo 1, Paola Maccioni 2, Gian Luigi Gessa 1,2
PMCID: PMC6494144  PMID: 16958983

ABSTRACT

The present paper focuses on the different lines of evidence indicating that cannabinoid CB1 receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB1 receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity‐related disorders.

Keywords: Body weight, Cannabinoids, CB1 Receptor Antagonists, Food Intake, Obesity, Overweight, Rimonabant, SR141716A

Full Text

The Full Text of this article is available as a PDF (85.8 KB).

REFERENCES

  • 1. Anthenelli RM, Dale R. Rimonabant helps cigarette smokers stop smoking and prevents post cessation weight gain: Results from the STRATUS‐US trial In: Final Program and Abstracts of 6th Annual Conference of SRNT Europe; Tübingen, Germany , 2004: 35. [Google Scholar]
  • 2. Arnone M, Maruani J, Chaperon F, Thiébot ME, et al. Selective inhibition of sucrose and alcohol intake by SR 141716, an antagonist of central cannabinoid (CB 1) receptors. Psychopharmacology 1997; 132: 104–106. [DOI] [PubMed] [Google Scholar]
  • 3. Bensaid M, Gary‐Bobo M, Esclangon A, et al. T he cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/([a‐z])a rats and in cultured adipocyte cells. Mol Pharmacol 2003;63: 908–914. [DOI] [PubMed] [Google Scholar]
  • 4. Carai MAM, Colombo G, Gessa GL. Rimonabant: The first therapeutically relevant cannabinoid antagonist. Life Sci 2005;77: 2339–2350. [DOI] [PubMed] [Google Scholar]
  • 5. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 2004;82: 863–869. [DOI] [PubMed] [Google Scholar]
  • 6. Chaperon F, Soubrié P, Puech AJ, et al. Involvement of the central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135: 324–332. [DOI] [PubMed] [Google Scholar]
  • 7. Chen RZ, Huang RR, Shen CP, et al. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 2004;999: 227–230. [DOI] [PubMed] [Google Scholar]
  • 8. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. LifeSci 1998;63: PL113–PL117. [DOI] [PubMed] [Google Scholar]
  • 9. Colombo G, Serra S, Vacca G, et al. Endocannabinoid system and alcohol addiction: Pharmacological studies. Pharmacol Biochem Behav 2005;81: 369–380. [DOI] [PubMed] [Google Scholar]
  • 10. Cota D, Marsicano G, Tschop M, et al. T lipogenesis. J Clin Invest 2003; 112: 423–431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. De Vry J, Schreiber R, Eckel G, et al. Behavioral mechanisms underlying inhibition of food‐maintained responding by the cannabinoid receptor antagonist/([a‐z])nverse agonist SR141716A. Eur J Pharmacol 2004;483: 55–63. [DOI] [PubMed] [Google Scholar]
  • 12. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353: 2121–2134. [DOI] [PubMed] [Google Scholar]
  • 13. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585–589. [DOI] [PubMed] [Google Scholar]
  • 14. Foltin RW, Brady JV, Fischman MW. Behavioral analysis of marijuana effects of food intake in humans. Pharmacol Biochem Behav 1986;25: 577–582. [DOI] [PubMed] [Google Scholar]
  • 15. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988;11: 1–14. [DOI] [PubMed] [Google Scholar]
  • 16. Freedland CS, Poston JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food‐maintained responding. Pharmacol Biochem Behav 2000;67: 265–270. [DOI] [PubMed] [Google Scholar]
  • 17. Gelfand EV, Cannon CP. Rimonabant: A selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Exp Opin Invest Drugs 2006; 15: 307–315. [DOI] [PubMed] [Google Scholar]
  • 18. Gessa GL, Orrù A, Lai P, et al. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology 2006; 185: 248–254. [DOI] [PubMed] [Google Scholar]
  • 19. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor‐dependent modulation of feeding. J Neurosci 2002;22: 9612–9617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Hajnal A, Norgren R. Accumbens dopamine mechanisms in sucrose intake. Brain Res 2001;904: 76–84. [DOI] [PubMed] [Google Scholar]
  • 21. Halikas JA, Goodwin DW, Guze SB. Marijuana effects. A survey of regular users. JAMA 1971; 217: 692–694. [DOI] [PubMed] [Google Scholar]
  • 22. Harrold JA, Elliott JC, King PJ, et al. Down‐regulation of cannabinoid‐1 (CB‐1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food Brain Res 2002;952: 232–238. [DOI] [PubMed] [Google Scholar]
  • 23. Harrold JA, Williams G. The cannabinoid system: A role in both the homeostatic and hedonic control of eating BrJNutrition 2003;90: 729–734. [DOI] [PubMed] [Google Scholar]
  • 24. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 2006; In press. [DOI] [PubMed] [Google Scholar]
  • 25. Higgs S, Williams CM, Kirkham TC. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after Δ9‐tetrahydrocannabinol, anandamide, 2‐arachidonoyl glycerol and SR141716. Psycho-pharmacology 2003;165: 370–377. [DOI] [PubMed] [Google Scholar]
  • 26. Hildebrandt AL, Kelly‐Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet‐induced obese mice. Eur J Pharmacol 2003;462: 125–132. [DOI] [PubMed] [Google Scholar]
  • 27. Hungund BL, Szakall I, Adam A, et al. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol‐induced dopamine release in the nucleus accumbens. J Neurochem 2003;84: 698–704. [DOI] [PubMed] [Google Scholar]
  • 28. Jbilo O, Ravinet‐Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567–1569. [DOI] [PubMed] [Google Scholar]
  • 29. Kirkham TC, Williams CM, Fezza F, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2‐arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550–557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obesity 2005; 29: 183–187. [DOI] [PubMed] [Google Scholar]
  • 31. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: A microdialy‐sis study. Pharmacol Biochem Behav 1996;53: 221–226. [DOI] [PubMed] [Google Scholar]
  • 32. McLaughlin PJ, Winston K, Swezey L, et al. T he cannabinoid CB1 antagonists SR141716A and AM251 suppress food intake and food‐reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003; 14: 583–588. [DOI] [PubMed] [Google Scholar]
  • 33. Milano WC, Wild KD, Hui YZ, et al. PCP, THC, ethanol, and morphine and consumption of palatable solutions. Pharmacol Biochem Behav 1988;31: 893–897. [DOI] [PubMed] [Google Scholar]
  • 34. Pi‐Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid‐1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO‐North America: A randomized controlled trial. JAMA 2006;295: 761–775. [DOI] [PubMed] [Google Scholar]
  • 35. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7: 65–72. [DOI] [PubMed] [Google Scholar]
  • 36. Pontieri FE, Tanda G, Di Chiara G Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995;92: 12304–12308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Ravinet Trillou C, Arnone M, Delgorge C, et al. A nti‐obesity effect of SR141716, aCB1 receptor antagonist, in diet‐induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284: R345–R353. [DOI] [PubMed] [Google Scholar]
  • 38. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet‐induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28: 640–648. [DOI] [PubMed] [Google Scholar]
  • 39. Rinaldi‐Carmona M, Barth F, Héauim M, et al. SR141716A, a potent and selective antagonist of the cannabinoid receptor. FEBS Lett 1994;350: 240–244. [DOI] [PubMed] [Google Scholar]
  • 40. Rinaldi‐Carmona M, Barth F, Congy C, et al. SR147778, a new potent and selective antagonist of the CB1 cannabinoid receptor. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004; 310: 905–914. [DOI] [PubMed] [Google Scholar]
  • 41. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001;159: 111–116. [DOI] [PubMed] [Google Scholar]
  • 42. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22: 565–572. [DOI] [PubMed] [Google Scholar]
  • 43. Simiand J, Keane M, Keane PE, et al. SR141716, aCB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9: 179–181. [PubMed] [Google Scholar]
  • 44. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005;30: 2035–2045. [DOI] [PubMed] [Google Scholar]
  • 45. Tanda G, Pontieri FE, Di Chiara G Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common ì1 opioid receptor mechanism. Science 1997;276: 2048–2050. [DOI] [PubMed] [Google Scholar]
  • 46. Tart CT. Marijuana intoxication: Common experiences. Nature 1970;226: 701–704. [DOI] [PubMed] [Google Scholar]
  • 47. Tonstad S. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006;16: 156–162. [DOI] [PubMed] [Google Scholar]
  • 48. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid‐1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1‐year experience from the RIO‐Europe study. Lancet 2005;365: 1389–1397. [DOI] [PubMed] [Google Scholar]
  • 49. Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non‐deprived rats. Neurosci Lett 2004; 354: 217–220. [DOI] [PubMed] [Google Scholar]
  • 50. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR1 41716, on food intake and body weight gain of obese (fa/([a‐z])a) compared to lean Zucker rats. Psychopharmacology 2003;167: 103–111. [DOI] [PubMed] [Google Scholar]
  • 51. Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005;6: 215–223. [DOI] [PubMed] [Google Scholar]
  • 52. Williams CM, Kirkham TC. A nandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143: 315–317. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES